Li Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Li Huang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Tao Tan
Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health) Institute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Zhejiang Provincial Clinical Research Center for Mental Disorders, the Affiliated Wenzhou Kangning Hospital, Wenzhou Medical University Wenzhou Zhejiang P. R. China
3 shared publications - Jie Yang
Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Institute of Aging, Key Laboratory of Alzheimer’s Disease of Zhejiang Province, Zhejiang Provincial Clinical Research Center for Mental Disorders, The Affiliated Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou, P.R. China
2 shared publications - Shumin Wu
Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Institute of Aging, Key Laboratory of Alzheimer’s Disease of Zhejiang Province, Zhejiang Provincial Clinical Research Center for Mental Disorders, The Affiliated Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou, P.R. China
2 shared publications - Tong Ye
Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Institute of Aging, Key Laboratory of Alzheimer’s Disease of Zhejiang Province, Zhejiang Provincial Clinical Research Center for Mental Disorders, The Affiliated Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou, P.R. China
2 shared publications Wei Wang
Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Institute of Aging, Key Laboratory of Alzheimer’s Disease of Zhejiang Province, Zhejiang Provincial Clinical Research Center for Mental Disorders, The Affiliated Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou, P.R. China
2 shared publications- Wenhua Shen
Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health) Institute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Zhejiang Provincial Clinical Research Center for Mental Disorders, the Affiliated Wenzhou Kangning Hospital, Wenzhou Medical University Wenzhou Zhejiang P. R. China
2 shared publications
Latest Publications
Suppression of Astrocytic PirB Alleviates Aβ‐Induced Excitotoxicity and Cognitive Deficits via EAAT Expression
Glutamate‐mediated neurotoxicity is a key factor in the pathogenesis of Alzheimer's disease, yet its regulatory mechanism and connection to the amyloid β (Aβ) cascade remain unclear. This study examined the role of the astrocytic Aβ receptor, PirB, on glutamate reuptake, excitotoxic neuronal death, and cognition. In vitro, primary astrocytes were treated with soluble PirB extracellular peptide (PEP), the PirB inhibitor Fluspirilene, or lentiviral vectors encoding PirB or shPirB. We measured excitatory amino acid transporter (EAAT) expression, intracellular glutamate levels, and calcium influx in astrocytes. We also evaluated neuronal apoptosis in neuron–astrocyte co‐cultures. PirB inhibition (via PEP or Fluspirilene) significantly increased EAAT1 and EAAT2 expression and activated the mTOR signaling. This was accompanied by elevated astrocytic glutamate levels, decreased intracellular calcium, as well as reduced neuronal apoptosis, whereas PirB overexpression had the opposite effects. In vivo, mice with astrocyte‐specific PirB conditional knockout (cKO) were injected with Aβ oligomers into the hippocampus and subjected to cognitive behavioral assays. Hippocampal neuronal loss and apoptosis were evaluated through Nissl and TUNEL staining. PirB cKO mice showed enhanced exploratory behavior, improved working memory, and higher EAAT expression, along with higher Bcl‐2/Bax ratios, mTOR activation, and reduced neuronal apoptosis compared with Aβ‐injected PirB flox/flox mice. Overall, our findings identify astrocytic PirB as a key driver of Aβ‐triggered glutamate‐mediated neurotoxicity and suggest that suppressing the PirB‐mTOR‐EAAT pathway could be a promising therapeutic strategy for mitigating Aβ‐related cognitive impairment.
Suppression of Astrocytic PirB Alleviates Aβ‐Induced Excitotoxicity and Cognitive Deficits via EAAT Expression
Glutamate‐mediated neurotoxicity is a key factor in the pathogenesis of Alzheimer's disease, yet its regulatory mechanism and connection to the amyloid β (Aβ) cascade remain unclear. This study examined the role of the astrocytic Aβ receptor, PirB, on glutamate reuptake, excitotoxic neuronal death, and cognition. In vitro, primary astrocytes were treated with soluble PirB extracellular peptide (PEP), the PirB inhibitor Fluspirilene, or lentiviral vectors encoding PirB or shPirB. We measured excitatory amino acid transporter (EAAT) expression, intracellular glutamate levels, and calcium influx in astrocytes. We also evaluated neuronal apoptosis in neuron–astrocyte co‐cultures. PirB inhibition (via PEP or Fluspirilene) significantly increased EAAT1 and EAAT2 expression and activated the mTOR signaling. This was accompanied by elevated astrocytic glutamate levels, decreased intracellular calcium, as well as reduced neuronal apoptosis, whereas PirB overexpression had the opposite effects. In vivo, mice with astrocyte‐specific PirB conditional knockout (cKO) were injected with Aβ oligomers into the hippocampus and subjected to cognitive behavioral assays. Hippocampal neuronal loss and apoptosis were evaluated through Nissl and TUNEL staining. PirB cKO mice showed enhanced exploratory behavior, improved working memory, and higher EAAT expression, along with higher Bcl‐2/Bax ratios, mTOR activation, and reduced neuronal apoptosis compared with Aβ‐injected PirB flox/flox mice. Overall, our findings identify astrocytic PirB as a key driver of Aβ‐triggered glutamate‐mediated neurotoxicity and suggest that suppressing the PirB‐mTOR‐EAAT pathway could be a promising therapeutic strategy for mitigating Aβ‐related cognitive impairment.
- 17 October 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (1) , 480-497
Advances in chemogenetics: a review of DREADDs and its application in psychiatric disorders
Chemogenetics is a rapidly advancing field that uses genetically engineered receptors to selectively modulate the activity of specific neuronal populations in the brain. This innovative approach allows for precise control of neural circuits, providing valuable insights into the roles of specific circuits in behavior and disease mechanisms. The potential of chemogenetics to transform our understanding of brain function could lead to novel therapeutic strategies for a wide range of neurological and psychiatric disorders. This review explores the fundamental mechanisms of chemogenetics, with a focus on Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) and their associated ligands. We provide a comprehensive overview of the various classes of DREADDs, detailing optimal ligand dosing and offering guidance for their integration into both research and clinical settings. Additionally, we examine the recent applications of DREADDs in psychiatry, particularly about brain regions and circuits involved in anxiety.
- 17 October 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (1) , 480-497
Advances in chemogenetics: a review of DREADDs and its application in psychiatric disorders
Chemogenetics is a rapidly advancing field that uses genetically engineered receptors to selectively modulate the activity of specific neuronal populations in the brain. This innovative approach allows for precise control of neural circuits, providing valuable insights into the roles of specific circuits in behavior and disease mechanisms. The potential of chemogenetics to transform our understanding of brain function could lead to novel therapeutic strategies for a wide range of neurological and psychiatric disorders. This review explores the fundamental mechanisms of chemogenetics, with a focus on Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) and their associated ligands. We provide a comprehensive overview of the various classes of DREADDs, detailing optimal ligand dosing and offering guidance for their integration into both research and clinical settings. Additionally, we examine the recent applications of DREADDs in psychiatry, particularly about brain regions and circuits involved in anxiety.
- Open Access
- 9 August 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 274
Comprehensive behavioral characterization and impaired hippocampal synaptic transmission in R1117X Shank3 mutant mice
Mutations in the Shank3 gene are strongly associated with various neurodevelopmental disorders, particularly autism spectrum disorder (ASD). The R1117X mutation, which results in truncated SHANK3 protein, has been implicated in dysfunctions in the striatum and cortex. However, its effects on hippocampal function remain poorly understood. In this study, we performed a comprehensive behavioral and synaptic analysis of homozygous R1117X Shank3 mutant mice. These mice exhibited deficits in sensory gating, motor coordination, and pain perception, alongside severe anxiety in novel environment. Additionally, they showed significant impairments in learning and memory, as well as abnormal spontaneous fine motor behaviors. Histological analysis revealed morphological changes in the hippocampus, which were coupled with deficits in synaptic transmission and plasticity. Notably, we observed a downregulation of glutamatergic receptors in the hippocampus, particularly NMDA receptor subtypes. Taken together, these findings demonstrate that the homozygous R1117X Shank3 mutant mouse represents a valuable model for investigating schizophrenia associated with intellectual disability. The altered hippocampal morphology, impaired synaptic function, and deficits in learning and memory observed in this model provide new insights into the underlying mechanisms of Shank3-related neurodevelopmental disorders.
- 9 August 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 274
Open AccessComprehensive behavioral characterization and impaired hippocampal synaptic transmission in R1117X Shank3 mutant mice
Mutations in the Shank3 gene are strongly associated with various neurodevelopmental disorders, particularly autism spectrum disorder (ASD). The R1117X mutation, which results in truncated SHANK3 protein, has been implicated in dysfunctions in the striatum and cortex. However, its effects on hippocampal function remain poorly understood. In this study, we performed a comprehensive behavioral and synaptic analysis of homozygous R1117X Shank3 mutant mice. These mice exhibited deficits in sensory gating, motor coordination, and pain perception, alongside severe anxiety in novel environment. Additionally, they showed significant impairments in learning and memory, as well as abnormal spontaneous fine motor behaviors. Histological analysis revealed morphological changes in the hippocampus, which were coupled with deficits in synaptic transmission and plasticity. Notably, we observed a downregulation of glutamatergic receptors in the hippocampus, particularly NMDA receptor subtypes. Taken together, these findings demonstrate that the homozygous R1117X Shank3 mutant mouse represents a valuable model for investigating schizophrenia associated with intellectual disability. The altered hippocampal morphology, impaired synaptic function, and deficits in learning and memory observed in this model provide new insights into the underlying mechanisms of Shank3-related neurodevelopmental disorders.